Abstract:Basing informed decisions on available, relevant information is essential in all phases of drug development. This is particularly true in early phase clinical trials, when our knowledge about toxicity of a new medicine remains limited. Thus, borrowing of information across seemingly disparate sources is appealing. Statistical literature has been written about augmenting a new clinical trial with data from historical studies designed for similar investigational purpose. But very few has looked into leveraging preclinical data into phase I first-in-man trials. The work presented in this thesis attempts to fill the gap by providing solutions in the Bayesian paradigm, with purposes of improving the design and analysis of adaptive phase I dose-escalation trials. Specifically, our focus is on the transition step of early drug development, where phase I clinical trials are preceded only with some preclinical information. We see preclinical data as a special type of historical data, say, historical animal data. This is not an obvious application of the existing approaches for data augmentation, since information collected from preclinical studies first needs to be translated to account for potential physiological differences between animals and humans. Furthermore, due to their intrinsic variabilities in drug metabolism, inconsistency between the translated preclinical and clinical data may still emerge however careful and correct the interspecies translation would be completed. We note this thesis will exclusively consider toxicity data, assuming that relationship between dose and risk of toxicity can be adequately described using a two-parameter logistic regression model. Grounded in Bayesian statistics, our idea is to represent preclinical data into a prior distribution for the dose-toxicity model parameters that underpin the human trial(s). Our aim is to propose robust Bayesian approaches, keeping in mind the possibility that toxicity in humans could be very different from what we have learnt in one or multiple animal species even after appropriate translation. The main challenge in statistical inferences is essentially to address issues of prior-data conflict emerging in a small trial. This thesis consists of two perspectives on the robust use of preclinical animal data. A “sensible” amount of animal data to be leveraged into the phase I human trial(s) is determined by either (i) assessing the commensurability of the prior predictions of human toxicity, which are obtained using animal data alone, with the observed toxicity outcomes from the ongoing trial(s), or (ii) fitting a hierarchical model with weakly informative priors placed on the variance parameters. Correspondingly, we have proposed a Bayesian decision-theoretic approach in Chapter 2 and a robust Bayesian hierarchical model in Chapter 3, which build the core of this thesis. We have also extended the Bayesian hierarchical model to address potential heterogeneity between patient groups in Chapter 4, where the methodology has been illustrated in the context of bridging strategies considered in phase I clinical trials planned in various geographic regions. Throughout, the proposed Bayesian adaptive methods have been elucidated with representative data examples and extensive simulations. Particular attention has been paid to balancing the information from different sources to draw robust inferences. Numerical results show that our proposals have desired properties. More specifically, preclinical data can be essentially discounted when they are in fact inconsistent with the toxicity in humans. In cases of consistency, benefits are seen as increased precision of estimate of the probability of toxicity at a range of doses, and higher proportion of patients allocated to the target dose(s).

The estimation and translation uncertainties in applying NOAEL to clinical dose escalation

Adaptive Dose Modification for Phase I Clinical Trials

Incorporating Human Exposure Information in a Weight of Evidence Approach to Inform Design of Repeated Dose Animal Studies.

Translating dosages from animal models to human clinical trials—revisiting body surface area scaling

BUILDING A DOSE TOXO-EQUIVALENCE MODEL FROM A BAYESIAN META-ANALYSIS OF PUBLISHED CLINICAL TRIALS

Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing

Retrospective analysis of a fatal dose-finding trial

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity

Dose translation between laboratory animals and human in preclinical and clinical phases of drug development

Evaluating the impact of anatomical and physiological variability on human equivalent doses using PBPK models

Bayesian adaptive methods to incorporate preclinical data into phase I clinical trials

Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection

Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling – A case study of doxorubicin with dose metrics considerations

Methods for Identifying a Default Cross-Species Scaling Factor

Comparative case study on NAMs: towards enhancing specific target organ toxicity analysis

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

A Systemic Exposure-Based Alternative to the Maximum Tolerated Dose for Carcinogenicity Studies of Human Therapeutics

Three steps towards dose optimization for oncology dose finding

Learning for Dose Allocation in Adaptive Clinical Trials with Safety Constraints

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility